Annals of oncology : official journal of the European Society for Medical Oncology
-
Docetaxel (T; Taxotere) with capecitabine (X) is active against metastatic breast cancer (MBC); bevacizumab (BV) has demonstrated efficacy with taxanes in the first-line setting. This study was conducted to assess the safety and efficacy of TX-BV in patients with MBC. ⋯ TX-BV demonstrated significant activity; dose modifications were required to manage drug-related toxic effects.